Waldenstr€ om macroglobulinemia (WM) is an immunoglobulin M-associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88 versus 13.9 years (95% CI: 6.4-29.3) for the MYD88 WT (P 5 0.86). The time-to-next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time-to-progression to active disease was 2.8 years (95% CI: 2.2-3.8) in the MYD88 L265P cohort and 1.9 years (95% CI: 0.7-3.1) in the
gain-of-function mutation, MYD88 L265P , has ushered a new era for WM, as valuable insights were gained regarding the signaling pathways in this malignancy. Recruitment of MYD88, following stimulation of TLR or IL-1R, to the activated receptor complex leads to IL-1R-associated kinase-1 (IRAK1) activation. Additionally, MYD88 L265P enhances Burton's tyrosine kinase (BTK) phosphorylation and transactivates hematopoietic cell kinase. 6 A leucine-to-proline substitution at position 265 of MYD88 protein triggers constitutive activation of nuclear factor jB, via both BTK and IRAK1, and enhances-cell proliferation and survival. 7 The MYD88 L265P mutation, while not exclusive to WM, 8, 9 has been variably identified in 70% to over 90% of patients with WM. [10] [11] [12] In contrast, the somatic CXCR4 WHIM mutations have been detected up to 43% of patients with WM. [13] [14] [15] [16] Clinically relevant information about patients' MYD88 mutation status remains sparse, and the existing data are primarily derived from single-center studies. 14, 17 Patients with
MYD88
WT genotype have not been studied extensively due to the low prevalence of this genotype. A recent study reported on the distinct clinical features, including older age at presentation, and an unexpectedly higher mortality of MYD88 WT patients with WM compared to patients harboring MYD88 L265P (mortality 38% vs. 6% during 4.84 years of follow-up, P < .0001). 14 No outcome differences were evident with respect to the patients' CXCR4 mutation status. 14 Notwithstanding the small size of the MYD88 WT WM cohort (n 5 15) and the occurrence of only a few events during the short study follow-up, 14 some experts consider the disease with MYD88 WT genotype to be an entirely separate entity, distinct from the typical WM associated with MYD88 gene mutation, and are proposing that the presence of MYD88 mutation be considered as a WM-defining feature. MYD88 mutation is an early oncogenic event involving the entire clone and present in 50%-80% of patients with IgM monoclonal gammopathy of undetermined significance (MGUS) and its presence has been recognized as an independent risk factor for progression of MGUS. 7, [18] [19] [20] [21] Our aim was to assess the impact of the MYD88 L265P mutation status on the natural history of patients with WM. Therefore, we compared clinical characteristics and outcomes of a large cohort of MYD88 L265P and MYD88 WT patients to assess the distinctive features and outcomes of the two patient populations. 16 The patients' MYD88 mutation status was assessed by the amplification-refractory mutation system, a variant of AS-PCR, 10 with an analytical sensitivity of 1% mutation detection in a wild-type background. 22 Patients who did not exhibit L265P mutation in the MYD88 (Figure 1 ).
| M E TH ODS

| Clinical presentation
The baseline clinical and laboratory characteristics are shown in 
| Primary treatment
The frontline therapies are outlined in Table 2 . Alkylating agents were used more frequently in MYD88 WT patients (n 5 34; 77%) than patients who harbored MYD88 L265P mutation (n 5 81; 54%), (P 5 .003). Nucleoside analogues were used in similar proportion of patients with MYD88 WT (n 5 3; 7%) or MYD88 L265P genotypes (n 5 6; 4%), (P 5 .4). Incidentally, the use of alkylating agents as frontline therapy was higher (77% versus 54%) in patients with MYD88 WT genotype, although there was no difference in the number of patients in the two cohorts who had the diagnosis of WM established prior to the year 2000, a period, in which alkylating agents were increasingly being used for treating WM, before rituximab made inroads. 28 Moreover, the disease characteristics and severity as assessed by the IPSS-WM, bone marrow involvement, and patients' performance status were similar between these two cohorts assessed at diagnosis of active WM. Therefore, the precise reasons for increased use of alkylating agents in the
MYD88
WT cohort remain unclear.
Interestingly, a higher median value of lactate dehydrogenase was noted in the MYD88 WT patient population, but the significance of this observation at this juncture is unclear. However, the proportion of patients who transformed to a histologically high-grade lymphoma or developed t-MDS was higher in the MYD88 WT cohort in our study. Previous studies that have demonstrated transformation to high-grade lymphoma or development of t-MDS in 1%-6% of cases did not stratify the patients according to their MYD88 mutation status. 29, 30 The increased incidence of these complications in our MYD88 WT cohort may be attributable to the greater use of alkylating agents and nucleoside analogues in this group. [29] [30] [31] [32] Although the results do not definitively establish a higher rate of development of secondary complications, a signal for an increased risk of t-MDS or transformation to high grade lymphoma in the MYD88 WT cohort will have to be further evaluated through prospective studies on uniformly treated cohorts. Notably the choice of frontline therapy for patients in our study was not dictated by their MYD88 mutation status since the predictive impact of alteration in this gene was not known until recently. Moreover, the disease characteristics and severity were similar between these two cohorts at the time of active disease and initiation of frontline treatment.
Interestingly, in our study, a shorter time to progression from smoldering to active disease was observed in patients with MYD88
WT genotype compared to those harboring the MYD88 L265P mutation. This difference did not reach statistical significance, possibly due to smaller sample size of patients with smoldering disease. However, this observation cannot account for the similar outcomes for the two cohorts with active WM, as survival estimates were specifically calculated from the time of active disease. A previous study conducted by our group, involving a larger cohort of patients with smoldering WM (n 5 48) has demonstrated that hemoglobin, bone marrow involvement and serum M-spike are independent predictors of disease progression. 33 While in our current analysis, as expected, a lower baseline hemoglobin and more extensive marrow involvement were observed in patients who ultimately progressed to active disease compared to those who remained in the smoldering state, a smaller sample size of patients with smoldering disease at diagnosis precludes our results from reaching statistical significance for these parameters in this subset.
An alteration in the MYD88 gene has been prospectively shown to serve as a predictive marker for patients on ibrutinib therapy. 34, 35 The major response rate to ibrutinib therapy in MYD88 mutant patient population was found to be substantially higher at 92% for MYD88 L265P ,
CXCR4
WT and 62% for MYD88
L265P
, CXCR4 WHIM population, compared to 0% in patients with MYD88 WT genotype. 16 In our study, ibrutinib was administered to a minority of patients. A few small studies have recently shown that other non-BTK inhibitor-based regimens are effective, irrespective of the MYD88 mutation status. [36] [37] [38] [39] It is possible that the patients in the other study 14 were primarily treated with BTK inhibitor-based therapies, leading to inferior outcomes for the 
MYD88
WT population, in contradistinction to our study, wherein nonibrutinib-based therapies were used as the mainstay of management.
We acknowledge the limitations of our study, including the inherent biases associated with the retrospective design involving a select, nonuniformly treated patient population at a single center.
Furthermore, our study lacks data with respect to CXCR4 as well as non-L265P MYD88 gene mutations. However, the patient outcomes in WM appear to be unaffected by the CXCR4 mutation status and this protein is overexpressed in WM cells irrespective of the patients' CXCR4 mutation status, 40 suggesting that the mutation in CXCR4 gene is unlikely to prognosticate patients, despite the association of CXCR4 WHIM with increased resistance to several therapies. [41] [42] [43] Although, it is possible that in the absence of deep sequencing studies, some patients in the MYD88 WT cohort could have harbored the non-L265P MYD88 mutations, and therefore, incorrectly categorized as
WT , such alterations (S219C, M232T, and S243N) are rarely encountered in WM, and therefore, unlikely to impact our findings. 7, 8, 35, 44 We purposely avoided analyzing progression-free survival due to irregular follow-up of patients in a retrospective study. TTNT in an indolent malignancy with specific indications for treatment has a greater relevance and was specifically analyzed. 36 Although it is possible that lower marrow burden (<10% LPL infiltrate) in some marrow samples on which MYD88 L265P was analyzed could have led to false negative results, it has been shown that AS-PCR accurately detects L265P mutation even when tumor burden is as low as 1.25%. 45 Our MYD88 assay is designed to detect a minimum of 1% mutant allele in a WT background which theoretically equals about 2% disease burden (assuming heterozygous mutations). Regardless, the OS data were not different even with the exclusion of those 10 patients classified under 
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